Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

CH1242303498
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG01BJ1BHZ3
OCS
Oculis Holding AG
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Biotechnology
NAME
Oculis Holding AG
ISIN
CH1242303498
TICKER
OCS
MIC
XNAS
REUTERS
OCS.OQ
BLOOMBERG
OCS US
Wed, 03.09.2025       Oculis Holding
CH1242303498

ZUG, Switzerland, Sept. 03, 2025 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a director of the Company....
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Mon, 01.09.2025       Oculis Holding
CH1242303498

ZUG, Switzerland, Sept. 01, 2025 (GLOBE NEWSWIRE) -- Phase 2 ACUITY trial results for Privosegtor (OCS-05) in acute optic neuritis to be presented in EURETINA late-breaking session...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Mon, 01.09.2025       Oculis Holding
CH1242303498

Phase 2 ACUITY trial results for Privosegtor (OCS-05) in acute optic neuritis to be presented in EURETINA late-breaking session...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Thu, 28.08.2025       Oculis Holding
CH1242303498

ZUG, Switzerland, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on developing innovative solutions for ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, announced today that Oculis’ management will participate in upcoming investor c...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Thu, 28.08.2025       Oculis Holding
CH1242303498

ZUG, Switzerland, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on developing innovative solutions for ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, announced today that Oculis’ management will participate in upcoming investor c...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Mon, 25.08.2025       Oculis Holding
CH1242303498

ZUG, Switzerland, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced the appointments of Mark Kupersmith, M.D. as Chief Medical Advisor, Neuro-O...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Mon, 25.08.2025       Oculis Holding
CH1242303498

ZUG, Switzerland, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced the appointments of Mark Kupersmith, M.D. as Chief Medical Advisor, Neuro-Op...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Thu, 21.08.2025       Oculis Holding
CH1242303498

ZUG, Switzerland, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced results for the second quarter ended June 30, 2025 and provided an o...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Thu, 21.08.2025       Oculis Holding
CH1242303498

ZUG, Switzerland, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced results for the second quarter ended June 30, 2025 and provided an...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Tue, 12.08.2025       Oculis Holding
CH1242303498

ZUG, Switzerland, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic conditions with significant unmet medical needs, today announced that Oculis’ management will be participating in the H.C. Wainwright 5th An...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Tue, 12.08.2025       Oculis Holding
CH1242303498

ZUG, Switzerland, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic conditions with significant unmet medical needs, today announced that Oculis’ management will be participating in the H.C Wainwright 5th Ann...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Fri, 01.08.2025       Oculis Holding
CH1242303498

ZUG, Switzerland, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that it has amended its loan facility (the “Amended Loan Agr...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Fri, 01.08.2025       Oculis Holding
CH1242303498

ZUG, Switzerland, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that it has amended its loan facility (the “Amended Loan Agr...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Wed, 09.07.2025       Oculis Holding
CH1242303498

ZUG, Switzerland, July 09, 2025 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to directors of the Company....
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Mon, 09.06.2025       Oculis Holding
CH1242303498

ZUG, Switzerland, June 09, 2025 (GLOBE NEWSWIRE) -- The attached notifications relate to the annual equity incentive awards granted to directors of the Company....
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Thu, 05.06.2025       Oculis Holding
CH1242303498

ZUG, Switzerland, June 05, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), today announced the results from its 2025 Annual General Meeting held on June 4, 2025 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 3:00 p.m. CEST / 9:00 a.m. EDT....
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Thu, 05.06.2025       Oculis Holding
CH1242303498

ZUG, Switzerland, June 05, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), today announced the results from its 2025 Annual General Meeting held on June 4, 2025 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 3:00 p.m. CEST / 9:00 a.m. EDT. ...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Tue, 03.06.2025       Oculis Holding
CH1242303498

ZUG, Switzerland, June 03, 2025 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company....
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Tue, 03.06.2025       Oculis Holding
CH1242303498

ZUG, Switzerland, June 03, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that Oculis will be participating in the following upcoming investor confe...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Tue, 03.06.2025       Oculis Holding
CH1242303498

ZUG, Switzerland, June 03, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that Oculis will be participating in the following upcoming investor confe...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Fri, 09.05.2025       Oculis Holding
CH1242303498

ZUG, Switzerland, May 09, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), today published the invitation to the 2025 Annual General Meeting, which will be held on June 4, 2025 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 3:00 p.m. CEST / 9:00 a.m. EDT....
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Fri, 09.05.2025       Oculis Holding
CH1242303498

ZUG, Switzerland, May 09, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), today published the invitation to the 2025 Annual General Meeting, which will be held on June 4, 2025 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 3:00 p.m. CEST / 9:00 a.m. EDT....
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Wed, 07.05.2025       Oculis Holding
CH1242303498

ZUG, Switzerland, May 07, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that Oculis will be attending and presenting at the following upcoming inve...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Wed, 07.05.2025       Oculis Holding
CH1242303498

ZUG, Switzerland, May 07, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that Oculis will be attending and presenting at the following upcoming inve...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Thu, 01.05.2025       Oculis Holding
CH1242303498

ZUG, Switzerland, May 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced upcoming presentations highlighting its innovative late-stage pipeline at E...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Thu, 01.05.2025       Oculis Holding
CH1242303498

ZUG, Switzerland, May 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced upcoming presentations highlighting its innovative late-stage pipeline at E...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Fri, 25.04.2025       Oculis Holding
CH1242303498

ZUG, Switzerland, April 25, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company, has issued registered ordinary shares of the Company, each with a nominal value of CHF 0.01. The issuance comprises 589,974 registered shares, reflecting the settlement of 310,941 shares...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Thu, 17.04.2025       Oculis Holding
CH1242303498

ZUG, Switzerland, April 17, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announces, in collaboration with EURETINA, the 2025 Ramin Tadayoni Award....
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Tue, 15.04.2025       Oculis Holding
CH1242303498

ZUG, Switzerland, April 15, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company"), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, will host an in-person and virtual R&D Day today, Tuesday, April 15, 2...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Tue, 15.04.2025       Oculis Holding
CH1242303498

ZUG, Switzerland, April 15, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company"), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, will host an in-person and virtual R&D Day today, Tuesday, April 15, 2...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Thu, 10.04.2025       Oculis Holding
CH1242303498

ZUG, Switzerland, April 10, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that it has completed enrollment in both Phase 3 DIAMOND-1 and DIAMOND-2...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Thu, 10.04.2025       Oculis Holding
CH1242303498

ZUG, Switzerland, April 10, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that it has completed enrollment in both Phase 3 DIAMOND-1 and DIAMOND-2...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Wed, 09.04.2025       Oculis Holding
CH1242303498

ZUG, Switzerland, April 09, 2025 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to directors of the Company....
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Tue, 01.04.2025       Oculis Holding
CH1242303498

ZUG, Switzerland, April 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company"), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that it will host an in-person and virtual R&D Day on...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Tue, 01.04.2025       Oculis Holding
CH1242303498

ZUG, Switzerland, April 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company"), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that it will host an in-person and virtual R&D Day on...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Thu, 20.03.2025       Oculis Holding
CH1242303498

ZUG, Switzerland, March 20, 2025 (GLOBE NEWSWIRE) -- The attached notifications relate to trades entered into by a PDMR of the Company pursuant to a 10b5-1 trading plan, in accordance with Rule 10b5-1(c)(1) of the Securities Exchange Act of 1934, as amended....
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Fri, 14.03.2025       Oculis Holding
CH1242303498

ZUG, Switzerland, March 14, 2025 (GLOBE NEWSWIRE) -- The attached notifications relate to annual equity incentive awards granted to members of the executive committee of the Company, as well as purchase of ordinary shares by a member of the Company´s Board of Direcors....
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Tue, 11.03.2025       Oculis Holding
CH1242303498

ZUG, Switzerland, March 11, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company"), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced results for the quarter and full year ended December 31,...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Tue, 11.03.2025       Oculis Holding
CH1242303498

ZUG, Switzerland, March 11, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company"), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced results for the quarter and full year ended December 31, 2...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Wed, 05.03.2025       Oculis Holding
CH1242303498

ZUG, Switzerland, March 05, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Oculis will be attending and presenting at the following upcoming investor conference:...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Mon, 03.03.2025       Oculis Holding
CH1242303498

ZUG, Switzerland, March 03, 2025 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company....
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Fri, 14.02.2025       Oculis Holding
CH1242303498

ZUG, Switzerland, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced the pricing of an underwritten offering of 5,000,000 of its...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Fri, 14.02.2025       Oculis Holding
CH1242303498

ZUG, Switzerland, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced the pricing of an underwritten offering of 5,000,000 of its...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Fri, 07.02.2025       Oculis Holding
CH1242303498

ZUG, Switzerland, Feb. 08, 2025 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting of earnout shares and associated removal of restrictions on these ordinary shares....
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Fri, 31.01.2025       Oculis Holding
CH1242303498

ZUG, Switzerland, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company, has issued registered ordinary shares of the Company, each with a nominal value of CHF 0.01, issued out of existing capital band (Kapitalband), for an aggregate of 2,500,000 ordinary share...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Mon, 20.01.2025       Oculis Holding
CH1242303498

ZUG, Switzerland, Jan. 20, 2025 (GLOBE NEWSWIRE) -- Attached is a Notification of Major Changes in Voting Rights....
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Mon, 06.01.2025       Oculis Holding
CH1242303498

Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential First-in-Class Neuroprotective Therapy...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Mon, 06.01.2025       Oculis Holding
CH1242303498

ZUG, Switzerland, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced positive topline results with OCS-05 in the Phase 2 ACUITY trial, which met the primary endpoint of safety and achieved statistica...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Fri, 03.01.2025       Oculis Holding
CH1242303498

ZUG, Switzerland, Jan. 04, 2025 (GLOBE NEWSWIRE) -- Attached is a Notification of Major Changes in Voting Rights, in relation to Brunnur vaxtarsjóður slhf‘s distribution of its shares in Oculis Holding AG to Brunnur Vaxtarsjóður slhf‘s shareholders....
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Fri, 29.11.2024       Oculis Holding
CH1242303498

ZUG, Switzerland, Nov. 29, 2024 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting of earnout shares and associated removal of restrictions on these ordinary shares....
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink